Triple-Targeted DNA Nanozyme Executes Disulfidptosis for Glioma Elimination

Targeting metabolic vulnerabilities, particularly mitochondrial dysfunction, has emerged as a promising therapeutic strategy for glioma. However, the precise induction of specific cell death pathways via non-genetic nanotherapeutics remains a significant challenge. Here, we report a triple-targeted DNA nanozyme designed to eliminate aggressive glioma by precisely inducing disulfidptosis.

A programmable nanoplatform, termed TMGH@AD, was constructed via rolling circle amplification. This system integrates three specific targeting ligands to facilitate blood-brain barrier (BBB) penetration, tumor accumulation, and mitochondrial localization. It also incorporates a G4/Hemin DNAzyme with peroxidase-mimicking activity and the mitochondrial-disrupting agent Alexidine (AD). The therapeutic efficacy and mechanism of action were evaluated both in vitro and in vivo.

Following systemic administration, TMGH@AD achieved sequential delivery to brain tumors and accurate mitochondrial localization. Within the mitochondria, the DNAzyme catalyzed the in situ generation of hydroxyl radicals (·OH). The synergistic reactive oxygen species (ROS) burst derived from the G4/Hemin nanozyme and the released AD triggered PTPMT1 dysregulation, catastrophic oxidative stress, and lipid peroxidation. This cascade led to substantial NADPH depletion and intracellular disulfide accumulation, ultimately executing disulfidptosis as the dominant cell death pathway.

This study presents a novel DNA nanozyme-based strategy that combines precise triple-targeted delivery with disulfidptosis activation. By overcoming delivery barriers and exploiting metabolic vulnerabilities, TMGH@AD offers a powerful therapeutic avenue for glioma eradication.